Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
Gossamer Bio has been the poster child for biotech companies struggling with IPO launches during the shutdown.
BioArctic AB to publish the company’s Full Year Report for the period January – December 2018 on Thursday, February 14, 2019 at 08:00 a.m. CET.
Despite a decline over the past year of class-action lawsuits, life science companies remain a popular target for securities fraud litigation.
The government shutdown threw a wrench into several biotech company’s plans for initial public offerings (IPOs). Although the government is only guaranteed to stay open until February 15, several biotechs are working to get their IPOs launched in that window. Here’s a look.
Suven Life Sciences Limited announced its Un-audited financial results for the quarter ended 31st December 2018.
Cash position of €207.2 million as of December 31, 2018, compared to €273.8 million as of December 31, 2017
Immunicum AB announced that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in February.
You have to give San Diego-based Gossamer Bio credit for the way it’s adapted its plans for an initial public offering (IPO) to deal with the government shutdown.
The subscription price for warrant TO1 in Promore Pharma AB has been determined according to the terms and conditions forthe warrants to 23.30 SEK per share.